Core Viewpoint - The low-temperature storage industry is under pressure, with Haier Biomedical reporting a decline in revenue and net profit for the first half of 2025, but showing signs of recovery compared to the second half of the previous year [1][2]. Financial Performance - Haier Biomedical's revenue for the first half of 2025 was 1.196 billion yuan, a year-on-year decrease of 2.27%, while net profit attributable to shareholders was 143 million yuan, down 39.09% [1]. - Despite the decline, revenue from low-temperature storage increased by 16.73% compared to the second half of the previous year [1]. New Industry Development - The proportion of revenue from new industries rose from 38% in 2023 to 47% in the first half of 2025, an increase of 7.27 percentage points year-on-year [2]. - Haier Biomedical has been actively acquiring companies in various sectors, including blood collection, temperature control, and laboratory solutions, to expand its new industry segment [3]. Market Position and Share - Haier Biomedical holds over 50% market share in plasma collection solutions and ranks among the top three in the automated medication market [4]. - The company has seen significant growth in its laboratory solutions, with its total organic carbon analyzers and UV spectrophotometers leading the domestic market [4]. International Expansion - Haier Biomedical is pursuing international markets with a localized strategy, having established a presence in over 150 countries and regions [5]. - In the first half of 2025, overseas revenue reached 427 million yuan, a year-on-year increase of 30.17%, with the second quarter showing a remarkable growth of 56.67% [6]. Future Outlook - The company anticipates further growth in overseas markets, particularly in Southeast Asia and the Middle East, driven by the expansion of medical infrastructure and the promotion of new industry solutions [7].